A novel mouse model of metastatic thyroid carcinoma using human adipose tissue-derived stromal/stem cells.
Kandil E., Hauch A., Friedlander P., Sheng M., Tsumagari K., Saeed A.
Animal Study, published in Anticancer Res (2013) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Anticancer Res (2013)
- Country
- Greece
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24122984
Abstract (original English)
Scientists have been in quest for the best in vivo model to evaluate chemotherapies for radioiodine-resistant metastatic thyroid carcinomas. Human adipose tissue-derived stromal/stem cells (ASCs) have been found to promote in vitro growth and in vivo tumorigenesis. In the present study, we describe a novel model of metastatic human thyroid carcinoma by combining ASCs with the papillary thyroid cancer, K1 cell line. Three groups of severe combined immunodefecient mice were investigated. The first group was injected subcutaneously with K1 cells plus ASCs, the second group with K1 cell only, and the last group with ASCs only. Mean tumor volumes and standard deviations were calculated and compared. Concomitant injection of ASCs with the K1 cell line led to the development of significantly larger tumors compared to the other groups (p<0.05). In addition, the lungs of this group demonstrated gross tumor metastasis and pathological features of high-grade neoplasms. In the present study we describe a novel mouse model using ASCs with the potential to be used for assessment of new treatments for the management of metastatic thyroid carcinomas.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.